Volume 99, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Parenteral ivermectin treatment of disseminated strongyloidiasis and hyperinfection is increasing, although not licensed in humans and with limited pharmacokinetic data available. Plasma and postmortem tissue analysis in an human immunodeficiency virus (HIV)/hepatitis C virus–positive man with disseminated strongyloidiasis suggests loading subcutaneous ivermectin doses are required, from which the central nervous system is protected.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Bisoffi Z, 2013. Strongyloides stercoralis: a plea for action. PLoS Negl Trop Dis 7: e2214. [Google Scholar]
  2. Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, Chen X, , 2014. Strongyloidiasis—an insight into its global prevalence and management. PLoS Negl Trop Dis 8: e3018. [Google Scholar]
  3. Mobley CM, Dhala A, Ghobrial RM, , 2017. Strongyloides stercoralis in solid organ transplantation: early diagnosis gets the worm. Curr Opin Organ Transpl 22: 336344. [Google Scholar]
  4. Mejia R, Nutman T, , 2012. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 25: 458463. [Google Scholar]
  5. Buonfrate D, Requena-Mendez A, Angheben A, Muñoz J, Gobbi F, Van Den Ende J, Bisoffi Z, , 2013. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 13: 7888. [Google Scholar]
  6. US FDA, Stromectal ® (Ivermectin). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050742s022lbl.pdf. Accessed May 5, 2018.
  7. Barrett J, Broderick C, Soulsby H, Wade P, Newsholme W, , 2016. Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literature. J Antimicrob Chemother 71: 220225. [Google Scholar]
  8. Looke DFM, McCarthy KL, McWhinney B, Clague A, Pillans P, , 2005. Strongyloides hyperinfection syndrome: low serum levels of ivermectin after oral and subcutaneous administration. Intern Med J 35: A73A88. [Google Scholar]
  9. Albonico M, 2016. StrongNet: an international network to improve diagnostics and access to treatment for strongyloidiasis control. PLoS Negl Trop Dis 10: e0004898. [Google Scholar]
  10. Einsiedel L, Fernandes L, , 2008. Strongyloides stercoralis: a cause of morbidity and mortality for indigenous people in central Australia. Intern Med J 38: 697703. [Google Scholar]
  11. Abdolrasouli A, McMillan A, Ackers JP, , 2009. Sexual transmission of intestinal parasites in men who have sex with men. Sex Health 6: 185194. [Google Scholar]
  12. Qu Z, Kundu UR, Abadeer RA, Wanger A, , 2009. Strongyloides colitis is a lethal mimic of ulcerative colitis: the key morphologic differential diagnosis. Hum Pathol 40: 572577. [Google Scholar]
  13. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC, , 2002. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 42: 11221133. [Google Scholar]
  14. Edwards G, , 2003. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J 2 (Suppl 1): S8. [Google Scholar]
  15. González Canga A, Sahagún Prieto AM, Diez-Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ, , 2008. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J 10: 4246. [Google Scholar]
  16. Steel JW, , 1993. Pharmacokinetics and metabolism of avermectins in livestock. Vet Parasitol 48: 4557. [Google Scholar]

Data & Media loading...

  • Received : 05 May 2018
  • Accepted : 02 Aug 2018
  • Published online : 17 Sep 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error